Earnings Report | 2026-04-16 | Quality Score: 95/100
Earnings Highlights
EPS Actual
$-0.04
EPS Estimate
$-0.0422
Revenue Actual
$1271789000.0
Revenue Estimate
***
Real-time US stock option implied volatility surface analysis and expected move calculations for trading strategies and risk management. We use options pricing models to derive market expectations for stock movement over different time periods and expiration dates. We provide IV analysis, expected move calculations, and volatility surface modeling for comprehensive coverage. Understand option market expectations with our comprehensive IV analysis and move calculation tools for options trading.
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Executive Summary
Tempus AI Inc. (TEM) has released its latest the previous quarter earnings results, marking the most recently available financial data for the precision medicine AI firm as of this month. The company reported quarterly revenue of approximately $1.27 billion, with an adjusted earnings per share (EPS) of -$0.04 for the quarter. The results cover the final quarter of the company’s prior fiscal year, and reflect both ongoing revenue growth from its core product lines and continued investments in res
Management Commentary
During the official earnings call, Tempus AI leadership focused on three core highlights from the quarter: expanded adoption of its AI-powered clinical decision support tools across U.S. oncology care networks, a series of new multi-year partnership agreements with top biopharmaceutical clients for clinical trial patient recruitment and real-world evidence generation, and progress in the development of its next-generation generative AI models designed to analyze genomic sequencing data for rare disease diagnosis. Management noted that the quarterly operating expense levels were aligned with previously disclosed investment plans, with a majority of new spending allocated to scaling R&D teams and expanding the company’s de-identified real-world patient data repository, which is a core input for its AI models. Leadership also emphasized that recurring revenue from enterprise biopharma clients grew at a faster rate than one-off service revenue during the quarter, a trend they view as a positive indicator of long-term customer retention.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Historical patterns still play a role even in a real-time world. Some investors use past price movements to inform current decisions, combining them with real-time feeds to anticipate volatility spikes or trend reversals.Historical patterns still play a role even in a real-time world. Some investors use past price movements to inform current decisions, combining them with real-time feeds to anticipate volatility spikes or trend reversals.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Professionals often track the behavior of institutional players. Large-scale trades and order flows can provide insight into market direction, liquidity, and potential support or resistance levels, which may not be immediately evident to retail investors.
Forward Guidance
Tempus AI did not issue specific numerical forward guidance alongside the the previous quarter earnings release, but outlined key strategic priorities for upcoming operational periods. These priorities include scaling deployment of its latest clinical AI tools to additional hospital systems, expanding commercial operations in select international markets, and continuing to invest in AI model training to improve the accuracy of its diagnostic and treatment recommendation tools. Analyst consensus estimates suggest that the company’s revenue growth may remain steady in upcoming periods, driven by broader industry adoption of AI in healthcare and life sciences workflows. However, market analysts also note that ongoing R&D and market expansion investments could potentially keep operating margins under pressure in the near term, as the company prioritizes market share capture over near-term profitability.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Evaluating volatility indices alongside price movements enhances risk awareness. Spikes in implied volatility often precede market corrections, while declining volatility may indicate stabilization, guiding allocation and hedging decisions.Cross-market correlations often reveal early warning signals. Professionals observe relationships between equities, derivatives, and commodities to anticipate potential shocks and make informed preemptive adjustments.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Scenario planning prepares investors for unexpected volatility. Multiple potential outcomes allow for preemptive adjustments.
Market Reaction
Following the release of the the previous quarter earnings results, TEM traded with near-average volume in subsequent sessions, reflecting mixed investor sentiment around the results. Sell-side analyst notes published after the call indicate that the reported revenue figure was roughly in line with consensus market expectations, while the adjusted EPS figure was slightly ahead of prior analyst estimates. Some market participants have focused positively on the company’s growing recurring revenue share and expanding partnership pipeline, while others have raised questions about the expected timeline for the company to reach positive adjusted operating margins. The broader healthcare AI subsector has seen heightened volatility in recent weeks, which may also be contributing to TEM’s post-earnings price action, as investors re-evaluate growth expectations for AI-enabled enterprise software firms across sectors.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Using multiple analysis tools enhances confidence in decisions. Relying on both technical charts and fundamental insights reduces the chance of acting on incomplete or misleading information.Volume analysis adds a critical dimension to technical evaluations. Increased volume during price movements typically validates trends, whereas low volume may indicate temporary anomalies. Expert traders incorporate volume data into predictive models to enhance decision reliability.TEM (Tempus AI Inc.) tops EPS estimates and posts 83 percent year over year revenue growth, shares fall 3.53 percent today.Cross-market correlations often reveal early warning signals. Professionals observe relationships between equities, derivatives, and commodities to anticipate potential shocks and make informed preemptive adjustments.